Loss of exclusivityJuly 2044latest FDA-listed patent expiry
CompanyKura Oncology →See this company's full patent-cliff portfolio
Drug detail
Brand name
KOMZIFTI
Active ingredient
ZIFTOMENIB
Strength
200MG
Dosage form
CAPSULE
Route
ORAL
Modality
Small molecule
FDA approval
November 2025
Marketing status
RX
Listed patents
Patent
Expires
Type
12521396
July 2044
product
12410184
July 2044
substance, product
11944627
September 2038
use U-4349
11673898
March 2037
use U-4351
10781218
March 2037
substance, product
10869868
January 2037
use U-4353
10077271
March 2036
substance, product
10174041
March 2036
use U-4354
Regulatory exclusivity
Code
Expires
NCE
November 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.